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Evaluation of Psoriasis Patients
Meda Sandra Orasan, Iulia Ioana Roman and Andrei Coneac
Abstract
Psoriasis represents a chronic inflammatory skin disease with multisystemic 
involvement. The development of this autoimmune disorder depends on a complex 
interplay of genetic and environmental factors. Besides presenting the conditions 
associated with psoriasis, the chapter outlines the role of hormones (sex hormones, 
prolactin, and thyroid hormones) in psoriasis pathogenesis and evolution. The 
chapter indicates the clinical approaches recommended in practice: a detailed medi-
cal history collection (including prior exposure to treatments and evaluation of 
co-medication), a thorough physical examination (with the completion of specific 
severity and QoL scales), laboratory investigations and screening for malignancies 
(including lymphoma and skin cancer) or infection (Tuberculosis, Crohn’s disease). 
European Guidelines encourage the dermatologist to check for hypersensitivity, 
metabolic, gastro-intestinal and renal disorders, check for the need of vaccines and 
contraception. We discuss pre-treatment, during-treatment and post-treatment 
evaluation options and underline the necessity of clear evaluation steps in the 
assessment of psoriasis patients.
Keywords: psoriasis, evaluation, genetic factors, comorbidities, sex hormones, 
prolactin, thyroid hormones, medical history, severity scales, DLQI, SkinDex, 
malignancies, tuberculosis, Crohn’s disease, metabolic syndrome, hepatitis
1. Introduction
Psoriasis is an inflammatory chronic skin disease, affecting over 100 million 
individuals worldwide [1, 2]. The development of this autoimmune disease depends 
on a complex interplay of genetic and environmental factors. In the immunological 
mediated process involved, the epidermal keratinocytes and mononuclear leuko-
cytes lead to the formation of the psoriatic lesion [3, 4]. The peripheral HTA axis of 
the skin modulates inflammatory mediators in response to stress and stress-related 
hormones that influence the disease development and the response to treatment. 
Besides stress, other endogenous factors with impact upon psoriasis are allergies and 
hormones [5–7]. Sex hormones and prolactin seem to have a major role in psoriasis 
pathogenicity, while glucocorticoids, epinephrine, thyroid hormones and insulin 
may influence psoriasis clinical manifestations [7]. Psoriasis has a multisystemic 
involvement and it is associated with several comorbid conditions: cardiovascular 
disease (hypertension, prothrombotic state, and atherogenic dyslipidemia), meta-
bolic syndrome (in which the main pathogenic factor is obesity with risk of develop-
ing insulin-resistance), nonalcoholic fatty liver disease and diabetes mellitus [5].
This chapter focuses on the clinical approaches to psoriasis patients that are 
reliable in practice. Besides describing the current status of psoriasis diagnosis, the 
chapter focuses on psoriasis comorbidities. The chapter also provides an objective 
Tailored Treatments in Psoriatic Patients
2
assessment of the main investigation tools: detailed medical history collection 
(including prior exposure to treatment and evaluation of comedication), the physi-
cal examination with a complete check for malignancies before and during psoriasis 
treatment (including lymphoma and skin cancer, evidence of active and chronic 
infection: Tuberculosis or Crohn’s disease), the dermatologic assessment with 
the completion of the objective scales (PASI/BSA/PGA; arthritis scales, comple-
tion of DLQI and checking for depression or anxiety signs. The major part of the 
chapter is devoted to the European Guidelines for special populations of psoriasis 
patients, that encourage the dermatologist to check for hypersensitivity, metabolic, 
gastro-intestinal and renal disorders, hepatitis or other hepatological dysfunctions, 
HIV, neurological and psychiatric diseases, to check also for the need of vaccines 
and contraception (must be pursued 20 weeks after discontinuation of biological 
therapy) and to pay attention to females with wish for pregnancy in the near future 
(pregnancy, breast-feeding, fertility).
We discuss three different categories of evaluation options: pre-treatment, 
during-treatment and post-treatment. The chapter presents the recommended 
laboratory investigations in pretreatment and when indicated by medical history 
or physical examination findings (usually every 2–5 months): blood count (Hb, 
Htc, leucocytes, platelets, differential blood count), CRP, liver enzymes (ALT, AST, 
AP, γGT), serum creatinine/eGFR, urine status (including urine pregnancy test 
in females), as for hepatitis B, C and HIV testing, they are optional only in some 
cases. Further specific testing may be required according to clinical signs, risk, and 
exposure.
The chapter also presents the great physical, emotional and social burden gener-
ated by psoriasis, (leading to an impaired quality of life that is often similar to that 
of patients who have heart failure and cancer), suggesting the need of psychological 
evaluation and support. In this context, we underline the necessity of a complete 
screening by using precise evaluation tools for the assessment of psoriasis patients.
2. Detailed medical history
The medical history section or case history of a patient starts by noting the 
patients’ gender and age. Psoriasis is considered equally prevalent in both sexes, 
even if some studies indicated that the disease is more common in men [5]. Psoriasis 
can occur at any age, but the average age of onset for psoriasis is 33 years and 
the two peaks of the disease onset are between 16 and 22 years of age and 57–60, 
respectively [6, 8]. It is important to determine the date/age of onset in order to 
classify psoriasis according to the date of onset into type I (onset before or at the 
age of 40, positive family history and frequent association with Human Leukocyte 
Antigen Cw6, noted HLACw6) or type II (onset after the age of 40, negative family 
history and normal frequency of the Cw6 allele [9]. Positive family history for 
psoriasis patients is common in 30% up to 90% of cases, as genetic factors have an 
important role in the disease susceptibility and expression [10–12]. Literature find-
ings present a threefold increased risk of developing psoriasis in monozygotic twins 
compared to fraternal twins [13]. Race of the patient is also important, as psoriasis 
is more common in Caucasians (3.6%), followed by African Americans (1.9%) and 
Hispanics (1.6%) [3, 4].
One of the most important things in collecting the information consists of lis-
tening to the patient carefully. The dermatologist must identify if other dermatolog-
ical, autoimmune, endocrinologic diseases, chronic illnesses or psychiatric disorders 
are present in the past medical history of the patient, and if positive, they should be 
properly investigated and treated. It is necessary to determine if associated factors 
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are present, such as: smoking, alcohol intake, metabolic syndrome, lymphoma, 
depression, melanoma, cardiovascular disease, respiratory disease, diabetes, kidney 
disease or arthritis. It has been reported that there is an association between smok-
ing and the development of psoriasis (also smoking increases the disease severity), 
as smoking leads to oxidative stress, which may stimulate chronic inflammation. 
Some literature data confirm that excessive alcohol intake may be a risk factor for 
psoriasis development [2].
One should document illnesses prior to the onset of psoriasis or other possible 
trigger factors in the previous months, such as stress, injury of skin, certain medi-
cation, infections which may determine psoriasis onset (streptococcus infection 
associated with guttate psoriasis onset) or flare-ups (earache, bronchitis, tonsillitis, 
respiratory infection) and allergies (with low scientific proof) [14]. The patient can 
usually tell if the onset of psoriasis was correlated to other medical issue or personal 
event. A study revealed that a recent life crisis was the trigger for plaque psoriasis in 
more than 45% of the cases, as stress represents the catalyst for the onset and later, 
the exacerbation of psoriasis [15–17]. The medication used by the patient should 
also be taken into consideration, as Lithium, Antimalarial, Inderal, Quinidine, 
Indometacin may induce psoriasis onset. Co-medication (with CYP3A4 enzyme 
inducers, warfarin, AINS, etc.) must be assess in order to prevent drug–drug inter-
actions or drug-triggered psoriasis. In most of the cases, the psoriatic lesions are 
induced by trauma (scratches, insect bites, vaccinations and sunburns) and appear 
7 to 14 days after injury, aspect called the Koebner sign or the isomorphic response. 
Psoriasis lesions can appear at all sites of the skin injury and the lifetime prevalence 
of the phenomenon ranges between 25 and 75% [18].
Physiological changes, such as childbirth, should be considered, too as pso-
riasis lesions slowly improve during pregnancy in 60% of the female patients, 
and if so, the same experience will be found across the next pregnancies. In some 
cases the stress attributed to childbirth will lead to the development of psoriasis. 
Postpartum, females will usually face a significant disease flare. More than 50% 
of the patients have genital involvement, raising discomfort in the delivery and 
postpartum period. During pregnancy and for breastfeeding patients, the treat-
ment options are unfortunately limited [19]. Other physiological changes such as 
menopause may affect psoriasis evolution, since dropping estrogen levels lead 
to psoriasis flares [7]. Some dermatologists consider that hormone replacement 
therapy during menopause with contraceptives does not affect psoriasis symptoms, 
therefore they do not recommend it [7].
The dermatologist should also focus on the chronology of the symptoms and 
complaints, which may include: worsening of a long-term erythematous scaly area, 
sudden onset of many small areas of scaly redness, pain (long-term rash with recent 
presentation of joint pain or joint pain with stiffness, pain, throbbing, swelling, 
tenderness, but without any visible skin findings), pruritus, sometimes fever, a 
viral infections, dystrophic nails, ocular findings such as redness and tearing due to 
conjunctivitis or blepharitis [20].
It is also important to assess how much does each of the above bother the patient 
[6]. The psychological impact of this skin disorder is severe in more than 62% of 
the patients with psoriasis, especially for those with disfiguring symptoms (scaling, 
redness etc.) on readily visible portions of the body [21, 22]. Patients with a longer 
disease history, particularly with the onset during childhood and adolescence, seem 
to be affected to a higher degree [14].
Next, the dermatologist must find out what type of treatment (topical, sys-
temic therapy and new oral treatment, phototherapy, biological through injection 
or perfusion, complementary or alternative treatments, etc.) the patients have used 
until now and with what outcome from their personal point of view. Finding out 
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what type of treatment the patient would prefer, in order to achieve a good patient 
compliance and disease management with the reduction of symptoms is important, 
too [23].
The patient will be questioned about the rate of the disease progression and 
if it has any season pattern. Fewer symptoms and flares have been reported dur-
ing summer and more during winter times. Psoriasis is an incurable, but treatable 
chronic condition, and symptoms may vary in severity and occur in cycles: active 
disease, flare-up, improvement or remission [24]. Patients should be asked if they 
can avoid some of the triggers, in order to reduce flare frequency and extend remis-
sion periods, which are common in almost half of the psoriasis population. Psoriasis 
is an unpredictable disease and spontaneous remission (without treatment) has 
been observed in some individuals [25].
3. Patients assessment
3.1 Dermatological examination
Psoriasis lesions consist of red, inflamed patches of skin with erythematous 
macules, that progress into maculopapules and well-demarcated, noncoherent, 
raised plaques with white micaceous scale, overlying a glossy homogeneous ery-
thema [1–5]. The dry flakes of skin scales result from the excessively rapid prolifera-
tion of skin cells triggered by inflammatory responses, the rapid overproduction 
leading to the buildup of skin cells.
Lesions may vary in size (from pinpoint papules to large plaques) and in distribu-
tion, but are usually found symmetrical on the scalp, postauricular skin, elbows, 
back, gluteal cleft, and knees. Clinical findings are variable among patients and can 
change quickly within the same patient [18]. Even after plaques have cleared, per-
manent dyschromia may be present. Literature reports state that the most common 
symptoms of psoriasis include: scaling of the skin in non-scalp areas (92% of cases), 
itching (72%), erythema (69%), fatigue (27%), swelling (23%), burning and bleed-
ing (20% of the individuals) [26]. Another study found rash (74% of cases), skin pain 
and scaling of scalp areas (62%), flare-ups (49%), joint pain of swollen, stiff joints 
(42%), skin cracking (39%), dry skin that may bleed or ooze (34%), physical discom-
fort (32%) and nail modifications (thick, ridged nails in 22% of patients) [27].
The diagnosis of psoriasis is clinical. Pinpoint bleeding caused by removing 
the scale is called the Auspitz sign and represents the dilated capillaries below the 
epidermis and thinned suprapapillary plate. A hypopigmented ring on the periph-
ery of an individual plaque, called Woronoff ring, may occur after treatment with 
UV radiation or topical steroids and is associated with lesional clearing and good 
prognosis [18].
Besides examining the patient’s skin and scalp for psoriasis lesions, the derma-
tologist should also check the nails, oral mucosa and tongue for specific signs of 
psoriasis.
3.2 Common psoriasis forms, classification according to phenotype
Findings on physical examination depend on the type of psoriasis present: 
Plaque Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis, Guttate psoriasis, 
Inverse Psoriasis or others including Scalp psoriasis and Nail psoriasis. The area 
of the skin involvement varies with the form of psoriasis. Psoriasis has a common 
etiology underlying diffuse erythroderma, or exfoliative dermatitis.
5Evaluation of Psoriasis Patients
DOI: http://dx.doi.org/10.5772/intechopen.79763
Classic plaque psoriasis also called chronic stationary psoriasis or psoriasis 
vulgaris is the most common type of psoriasis, affecting 58–97% of patients [28, 
29]. It is characterized by inflammatory red, sharply demarcated, raised, dry, differ-
ently sized erythematous plaques covered by thick silver or white scale and variable 
shape or diameter with a predilection for scalp and retroauricular regions, extensor 
surfaces (especially elbows and knees), trunk and lumbosacral area.
Pustular psoriasis presents as clearly defined, raised, small, coalescing pus-
tules, filled with non-infectious pus, appearing generalized (diffusely over the body 
as a single episode, called von Zumbusch variant, accompanied by fever and intense 
ill feeling) or localized to the distal extremities (palms, fingertips, nails and soles 
of feet, called Acrodermatitis continua of Hallopeau). Pustular psoriasis affects 
between 1 and 12% of cases, and patients may cycle through erythema, pustules, 
then scaling [29, 30].
Erythrodermic psoriasis typically occurs in 0.4–7% of cases, in people with 
unstable plaque psoriasis and presents as a deep red rash all over the body, with 
burned look skin and shedding of skin in sheets, instead of small scales with severe 
pain and itching. It may be accompanied by fluctuating body temperature (fever, 
chills, hypothermia), dehydration secondary to the large body surface area involve-
ment, fluid retention with ankle swelling. It represents a potentially life-threatening 
situation, as the patient may experience cardiac instability and hypotension due to 
massive vascular shunting in the skin, and may pneumonia [29, 30].
Guttate psoriasis is characterized by small red 1–10 mm in diameter drops-
like papules and plaques, predominately on the trunk, arms and legs. It classically 
appears suddenly in 0.6–20% of patients in childhood or adolescence, approxi-
mately 2–3 weeks after a streptococcal infection of the upper respiratory tract or 
other infection [29, 31].
Inverse or intertriginous psoriasis affects 12–26% of patients and it is charac-
terized by smooth, flat, deep-red or white, inflamed lesions wet patches or plaques 
without scaling, due to the moist nature of the areas affected: flexural skin folds, 
axillae, antecubital fossae, inframammary creases, umbilicus, groins and genital 
area, gluteal cleft, popliteal fossae or body folds [30, 32].
Scalp psoriasis affects approximately 50% of patients and is characterized by 
erythematous raised plaques with silvery white scales on the scalp. Severe forms 
may induce sever dandruff and itching, even hair loss [33].
Nail psoriasis occurs in 4–69% of psoriasis patients and may cause pits on the 
nails and oil spots (specific findings, caused by exocytosis of leukocytes beneath 
the nail plate), also generating a thickened and yellowish nail, that can be confused 
with nail fungus [34]. Onycholysis can occur due to the parakeratosis of the distal 
nail bed, and one or more nails can associate with severe nail destruction or loss, 
restricting manual dexterity [5]. Psoriatic nails develop onychomycosis or bacte-
rial infections in 4–30% of the cases, because of the nail separation and subungual 
debris [31, 35]. Patients with nail psoriasis have significantly higher psoriasis 
severity scores, days unfit to work and lower quality of life (QoL) compared to those 
without nail involvement [36].
Oral psoriasis may present with whitish lesions on the oral mucosa, changing 
daily in severity and can trigger different symptoms (oral pain, burning or change 
in taste perception) that resemble other conditions affecting the mouth and lips, 
such as stomatitis, oral thrush, or chronic eczema. It may also present as severe 
cheilosis with extension onto the surrounding skin, crossing the vermillion border. 
Psoriasis patients may be prone to develop the geographic tongue (unpainful red 
areas of varying size surrounded by a white border, appearing on the top and sides 
of the tongue), considered to be an oral form of psoriasis [37].
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3.3 Psoriasis diagnostic by biopsy
Most cases of psoriasis are diagnosed clinically, but some pustular forms are 
difficult to recognize. Punch biopsy of the skin may act as a confirmatory workup 
procedure for atypical cases and exclude other conditions in cases of diagnostic 
uncertainty: atopic dermatitis (eczema), tinea corporis (ringworm), pityriasis rosea 
or rubra pilaris, seborrheic dermatitis, etc. Biopsy of acral skin may be less useful for 
the clinician as chronic eczematous dermatitis may be psoriasiform, while psoriasis 
of the palms and soles may show spongiosis more often associated with eczema [38].
3.3.1 Procedure
After local disinfection with alcohol, iodine or similar solution, the local anes-
thesia is usually performed with 1% lidocaine with epinephrine. After a wait time 
of 10 minutes (for maximum vasoconstriction), the punch tool (a 4 or 6 mm-punch 
biopsy for vertical sectioning) is placed on top of the skin. The pressure is applied 
until the sampling goes down to subcutis, then with the help of a needle tip, the 
excised skin is removed. The skin defect can be closed with classic stitches (removed 
in 10–14 days) or dissolving stitches (dissolving in 6–8 weeks), still in most of the 
cases the wound is left open.
Another method that can be used is the shave biopsy. A thin sliver of skin is 
shaved off using a very sharp blade, causing some bleeding. The dermatologist will 
apply pressure to the area, apply a dressing and sometimes a topical medicine [39].
3.3.2 Biopsy results
Biopsy of the skin lesion may reveal basal cell hyperplasia, proliferation of 
subepidermal vasculature, absence of normal cell maturation and keratinization, 
neutrophils aggregation in the epidermis.
The following histologic dermal findings are present:
• signs of inflammation throughout the dermis
• marked hypervascularity and enlarged dermal papillae
• an activated CD3+ lymphocytic infiltrate around blood vessels
• neutrophils aggregation in the dermis that extends up into the epidermis
The histologic epidermal findings include the following:
• Mitotic activity of basal keratinocytes is increased almost 50-fold, with kera-
tinocytes migrating from the basal to the cornified layers in only 3–5  days 
rather than the normal 28–30 days. Stratum corneum contains flattened nuclei 
(parakeratosis).
• Abnormal keratinocyte differentiation throughout the psoriatic plaques is man-
ifested by the loss of the granular layer.
• The epidermis becomes thickened or acanthotic and the rete ridges are increased 
in size. The epidermis can be variably spongiotic.
7Evaluation of Psoriasis Patients
DOI: http://dx.doi.org/10.5772/intechopen.79763
• Two findings are pathognomonic for psoriasis and can be found in active plaque 
psoriasis, also in the pustular form:
a. Microabcess of Munro –collections of neutrophils are sandwiched between 
layers of parakeratotic stratum corneum, surrounded by parakeratosis.
b. Spongiform pustule of Kogoj—accumulation of neutrophils within a spongio-
tic pustule [40, 41].
4. Evaluation of psoriasis complications and associated diseases
Besides skin, nails and mucosa assessment in psoriasis patients, an eye and 
joints checkup should also be performed. Screening is needed for the most com-
mon psoriasis comorbidities: cardiovascular disease (hypertension, prothrom-
botic state, atherogenic dyslipidemia), metabolic syndrome (central obesity, 
atherogenic dyslipidemia, systemic arterial hypertension, insulin resistance), 
type 2 diabetes mellitus, nonalcoholic fatty liver disease. Long-term monitoring 
is indicated and it is specific for the type of psoriasis treatment applied: screening 
for cancers (skin cancers after phototherapy and lymphomas after systemic treat-
ment with immune-suppressing medications), screening for active and chronic 
infections (Tuberculosis or Crohn’s disease after biologic treatment), screening 
for liver disease (in systemic treated patients with methotrexate), and kidney 
disease etc.
4.1 Ocular involvement assessment
Ocular findings are common in 10% of patients, and the skin is usually affected 
first and afterwards the lid, conjunctiva and cornea. Blepharitis is the most com-
mon ocular finding in psoriasis patients, followed by dry eyes with lower incidence. 
Blepharitis is diagnosed by clinical examination, slit-lamp examination or swabbing 
the skin for bacterial and fungic testing.
Psoriasis may determine madarosis, cicatricial ectropion and trichiasis, even 
loss of the lid tissue, chronic nonspecific conjunctivitis (pink eye) and conjunctival 
hyperemia, and corneal dryness with a frequent punctate keratitis (inflammation of 
the cornea) and corneal melt [42, 43].
Acute anterior uveitis is usually associated with psoriatic arthritis and tends 
to be bilateral, prolonged, and more severe than nonpsoriatic cases. Diagnostic of 
acute anterior uveitis is challenging and it is performed based on clinical aspect, 
examination with slit-lamp (white blood cells accumulate in the fluid filled space 
in the front of the eye, in the anterior chamber) and basic workup for syphilis and 
sarcoidosis testing, for HLA-B27, tuberculosis or viral etiology screening (herpes 
simplex, herpes zoster, cytomegalovirus) [44].
4.2 Joint involvement assessment
Psoriatic arthritis affects approximately 10–30% of psoriasis patients and is 
characterized by stiffness, pain, throbbing, swelling, tenderness of the joints and 
progressive joint damage. Peripheral arthritis, spondylitis, enthesitis (inflam-
mation of the sites where tendons insert into the bone), arthritis in the fingers 
and dactylitis (profuse swelling of the fingers or toes) are the most common 
manifestations.
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The large joints are occasionally affected, but the distal joints, such as the 
fingers, toes, wrists, knees, and ankles are most often involved. In more than 20% 
of the cases, arthritis symptoms occur before the psoriasis ones [2].
Psoriasis severity and certain locations (the scalp and intergluteal and/or peri-
anal region) have been associated with the development of psoriatic arthritis (PsA) 
[45]. Also, a retrospective study from 2014 on more than 4000 patient’s reports that 
nail involvement in psoriasis was a significant predictor of the patient also having 
psoriatic arthritis [46]. Earlier age of onset of psoriasis had a positive correlation 
with the development of PsA, suggesting that the disease duration and inflamma-
tory burden over time have an important part [47]. Arthritic changes cannot be 
reversed and may be may be mutilating and debilitating, suggesting the need of 
early treatment initiation. Patients who suffer also of osteoarthritis or rheumatoid 
arthritis of the finger joints have a higher risk to develop arthritis mutilans, in which 
bones are resorbed, leading to a collapse of the soft tissue (telescopic fingers of the 
hands).
Radiographs of affected joints can facilitate the diagnosis of psoriatic arthritis. 
Bone scans usually identify early joint involvement. Arthritis patients must be 
periodically screened with review of systems and physical examination and imag-
ing tests.
The differentiation of psoriatic arthritis from rheumatoid arthritis and gout can 
be facilitated by the absence of the typical laboratory findings of those conditions 
and the radiographic aspect of the affected joints. Overlap with other arthritic 
syndromes is also possible.
4.3 Screening for cancers
The risk of cancer in patients with psoriasis remains a cause of special concern. 
The risk of carcinogenesis can occur due to the chronic inflammatory nature of 
psoriasis, the type of treatment applied (past immunosuppressive therapies such 
as MTX and cyclosporine immune-suppressive, PUVA or phototherapy), the 
increased prevalence of comorbid and other risk factors for cancer (smoking and 
obesity) [48, 49].
Cutaneous malignancies (melanoma and non-melanoma skin-cancer) seem to 
be directly related to phototherapy performed by the psoriasis patients. A signifi-
cantly increased risk for SCC and BCC was detected in psoriasis patients treated 
with higher doses of PUVA compared to lower doses [52]. Scientists suggested that 
this malignancy risk can be decreased by using sunscreen or trying to stay out of 
the sun, and cease smoking, a risk factor for both psoriasis patients and skin cancer. 
Malignancy records for psoriasis patients also mention the development of leuke-
mia, prostate, pancreatic, breast and colon cancer.
Latest data suggests patients with more severe psoriasis have an increased risk 
of cancer-related mortality, this association being the strongest for lymphopro-
liferative malignancies and cutaneous malignancies [50, 51]. The increased risk 
is likely linked to male gender, advancing age or COPD in patients with psoriasis 
arthritis [53].
Even though long-term control trials and observational studies are still needed, 
the addition of malignancy as a potential adverse event has been added in the medi-
cation packaging of biological therapies [48, 54]. Specific medications have raised 
concern in concurrent use, being suspected to increase the risk of malignancy: 
the addition of a biologic agent to potent immunosuppressive treatments, also the 
use of AZA, 6-MP, cyclosporine, or cyclophosphamide with TNF blockers [48]. 
According to published guidelines, a history of lymphoma, represents an absolute 
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contraindication to TNF-antagonist therapy, while biologic therapy is contraindi-
cated in patients with an active or recent (within 5 years) history of malignancy, 
with the exception of treated nonmelanoma skin cancers.
For cutaneous malignancy detection, skin self-examination would be the first 
step, followed by complete skin examination performed by the dermatologist, with 
the use of dermoscopy and histopathological results confirmation after excision of 
the lesion.
For both Hodgkin and non-Hodgkin types of lymphoma, a specific screening 
test is not available and for a definitive diagnosis a biopsy is required. For leukemia, 
no screening test is available, but the condition may be detected through a Chest 
X-ray or CAT scan (showing swollen lymph nodes or signs of infection), Spinal tap 
(presence of leukemia cells in the cerebrospinal fluid), Bone marrow aspiration and 
biopsy from the hip bone (the existence of leukemia cells in the bone marrow).
The lung cancer screening is recommended to be performed each year by Low-
dose helical or spiral computed tomography (CT) scan. to people aged 55 to 80 who 
have smoked for 30 pack years or more or who have quit within the past 15 years. 
People who routinely used tobacco products and/or drink alcohol should receive 
general health screening examination at least once a year for the detection of head 
and neck cancer.
Breast cancer screening should start with the patient’s self-examination, fol-
lowed by clinical breast examination and mammography over the age of 45 years 
old, and in some cases magnetic resonance imaging is used.
Screening and diagnostic of prostate cancer is recommended over the age of 
50 years old and it is performed by digital rectal examination and prostate-specific 
antigen test.
According to the latest recommendations, for patients over the age of 50 years 
old, colorectal cancer screening primary tests should be used (guaiac-based fecal 
occult blood test or fecal immunochemical test every year), followed by flexible 
sigmoidoscopy every 5 years or colonoscopy every 10 years [54].
4.4 Screening for active and chronic infections
Mild to serious secondary infections can occur directly related to the immune-
suppressing medication during psoriasis treatment.
People with HIV seem to be more likely to develop psoriasis. Clinical observa-
tion suggests that HIV-1 infection can trigger new-onset psoriasis or exacerbate 
existing psoriasis. As HIV-1 infection progresses and CD4+ T cell counts decrease, 
psoriasis can worsen. According to the Centers for Disease Control and Prevention 
HIV screening should be performed at least once by patients over 13 years old 
and pregnant women and more often for people with risk factors such as: having 
unprotected sex with positive or unknown HIV status subjects or multiple part-
ners, injecting drugs and sharing needles, syringes, etc. There are three testing 
methods for HIV: antibody tests (detect HIV infection from blood or saliva about 
3 to 12 weeks from the time of infection), combination tests (antibody/antigen 
tests detect HIV infection from blood about 2 to 6 weeks from the time of infec-
tion) and the very expensive nucleic acid tests (NATs) (detect HIV infection from 
blood sample about 7 to 28 days from the time of infection). The combination of 
two methods is highly accurate and recommended for all patients.: if antibodies are 
detected by initial ELISA method testing, the second test will be performed using 
the Western blot procedure [55].
Literature data indicate that immunosuppressive and immunomodulatory 
therapies for psoriasis and psoriatic arthritis are risk factors for allowing latent TB 
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to transform into active TB in some patients. The consensus statement from 2008 
of the National Psoriasis Foundation recommended all patients to be screened for 
latent TB infection prior to initiating any immunologic therapy with systemic and 
biologic agents, also recommended that delaying immunologic therapy should be 
performed until latent TB infection prophylaxis is completed [56].
4.5 Screening for liver disease
Dermatologists should also screen psoriasis patients for hepatitis B virus (HBV) 
using triple serology testing: hepatitis B surface antigen, hepatitis B surface anti-
body, and hepatitis B core antibody, before beginning treatment with tumor necro-
sis factor (TNF) inhibitors or biologics (including ustekinumab and secukinumab), 
according to the latest recommendations.
If the patient is at risk for reactivation of HBV, liver function tests, hepatitis 
B surface antibody, hepatitis B core e antigen, and HBV DNA should also be 
tested. Routine follow-up with testing for reactivation should continue for at least 
6 months after the TNF inhibitor is discontinued. In case of patients suffering of 
chronic HBV for whom biologics are considered, etanercept is recommended as 
first-line therapy [56].
As far as the systemic treated patients with methotrexate are concerned, the 
screening should be made in order to evaluate the liver injury. Besides the liver 
function tests, the liver biopsy was performed, but it was associated with significant 
morbidity and mortality. A recent Australasian position statement recommends 
transient elastography (which measures the speed of shear waves used to estimate 
hepatic tissue stiffness) for monitoring methotrexate therapy, repeated every 
3 years if kPa < 7.5 and yearly if kPa > 7.5 [57].
4.6 Screening for kidney disease
The association of psoriasis with kidney disease in recent studies expands 
the list of bodily systems that psoriasis is affecting beyond the skin. The kidney 
seems to be both a target of classic cardiovascular risk factors and susceptible to 
the toxic effects of psoriasis traditional drugs. Medication such as cyclosporine 
and methotrexate may have contributed somewhat to the increased frequency 
observed [58].
Moderate to severe psoriasis, affecting over 20% of patients worldwide has been 
linked to a higher risk of kidney disease. The analysis performed on 143,883 psoria-
sis medical records in the United Kingdom concluded that severe psoriasis subjects 
were twice as likely to acquire chronic kidney disease compared to those with mild 
psoriasis or no psoriasis at all. Latest reports show that psoriatic arthritis is an 
independent predictor of renal damage in patients with psoriasis [59].
Several studies demonstrated a greater incidence of proteinuria and elevated 
creatinine in patients suffering from psoriasis [60]. Patients with psoriasis and/
or psoriatic arthritis, particularly when they are candidates for systemic therapy, 
should be screened for an underlying renal damage by laboratory tests including 
glomerular filtration rate and a simple urine test to screen for albuminuria (albu-
min/creatinine ratio).
4.7 Screening for gastrointestinal disease
Gastrointestinal disease screening is indicated in patients with decreased growth 
rate, unexplained weight loss, or symptoms of inflammatory bowel disease. Celiac 
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disease, sclerosis and the inflammatory bowel disease (Crohn’s disease) are autoim-
mune disorders, which may be present in psoriasis patients.
In Celiac disease, an autoimmune gluten-induced bowel disease, the small 
intestine is affected, leading to gastrointestinal manifestations (diarrhea and 
steatorrhea, weight loss) and malabsorption-related problems (folic acid, cal-
cium, vitamin D and selenium malabsorption, cooper and zinc deficiencies, iron 
deficiency or megaloblastic anemia) [61]. Celiac patients have an increased risk of 
developing adenocarcinoma and lymphoma of the small bowel. Screening for Celiac 
disease is performed with anti-transglutaminase and anti-endomysial antibodies, 
both having high sensitivity to diagnose patients with classic symptoms and com-
plete villous atrophy and also 50% of the patients with minor mucosal lesions with 
normal villi. Professional guidelines recommend that a positive blood test must be 
followed by endoscopy/gastroscopy and biopsy. Checking total serum IgA level is 
also indicated and if negative, anti-DGP antibodies (antibodies against deamidated 
gliadin peptides) should be determined [62].
Crohn’s disease, a type of inflammatory bowel disease (IBD), may affect 
any part of the gastrointestinal tract and presents gastrointestinal, systemic 
and extraintestinal manifestation. The diagnosis of Crohn’s disease can some-
times be challenging and may take several years. A colonoscopy with a biopsy 
is the recommended test for diagnosis and it is approximately 70% effective in 
diagnosing the disease [63]. It allows direct visualization of the colon and the 
terminal ileum, identifying the pattern of disease involvement and presentation: 
stricturing, penetrating or inflammatory type. Modern investigation options 
of the small-bowel disease are the computed tomographic enteroclysis (hybrid 
technique that combines the methods of fluoroscopic intubation-infusion small 
bowel examinations with that of abdominal CT) and the capsule endoscopy, 
with a specific role in the investigation of Crohn disease. Blood determina-
tions for anemia or infections are recommended, as well as a total blood count, 
erythrocytes sedimentation rates, body mineral levels and protein levels deter-
mination. Stool samples are checked for occult blood loss or infectious microbes. 
Expert guidelines do not currently recommend antibody or genetic testing for 
Crohn’s disease, but the Saccharomyces cerevisiae antibodies (ASCA) and anti-
neutrophil cytoplasmic antibodies(ANCA) are used to identify inflammatory 
diseases of the intestine and to differentiate Crohn’s disease from ulcerative 
colitis [64].
Folate or acid folic deficiency represents the deficiency of B9 vitamin, vital 
for proper nerve function and preventing birth defects, also normalizing the high 
levels of homocysteine, which can increase the risk of heart disease. Folate defi-
ciency is common in subjects with celiac disease or Crohn’s disease. Patients with 
severe psoriasis seem to have a higher risk of developing folate deficiency [65]. 
The mechanism is believed to be an impaired absorption of folate and an excess 
loss of folate in the skin scales of patients suffering from psoriasis and mycosis 
fungoides [66]. In the screening of acid folic deficiency, ruling out cobalamin 
deficiency (vitamin B12) is important, as both cause megaloblastic anemia 
and neurologic manifestations, the serum folate level cannot be used alone to 
establish the diagnosis of folate deficiency. Additional follow-up tests include 
serum homocysteine (which is elevated in vitamin B-12 and folate deficiency) 
and serum methylmalonic acid (which is elevated in vitamin B-12 deficiency 
only). A recent study pointed out that 75% of the psoriasis patients treated with 
methotrexate in UK receives folic acid supplementation. Literature confirms 
a reduction in the adverse effects of MTX, but it questions if this may impact 
efficacy [67].
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4.8 Screening for Parkinson’s disease
Patients with psoriasis have a higher risk of developing Parkinson’s disease 
probably due to the detrimental effect of chronic inflammation on the neuronal 
tissue [68]. Risk factors for this association from FDA reports would be: male gen-
der, age over 60 years old, previous Azilect treatment and presence of high blood 
pressure. Latest findings suggest that an immune response to alpha-synuclein 
proteins (which accumulate inside the brain of Parkinson’s disease patients) play 
a role in the disease, suggesting an autoimmune etiology. Diagnosis of Parkinson 
disease is challenging because of the highly variable clinical aspect and lack of 
reliable objective test. Still it is the updated diagnostic criteria that must guide the 
clinician [69].
4.9 Screening of polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) in female psoriasis patients has a remark-
ably higher prevalence than in age- and BMI-matched control women. Women 
who present both PCOS and psoriasis are more likely to have insulin-resistance, 
hyperinsulinemia, reduced HDL cholesterol levels and a more severe degree of skin 
disease, compared to patients who suffer only of psoriasis. Similar to psoriasis, the 
components of metabolic syndrome seem to be closely related to PCOS as well. The 
ovulatory phenotype of the disease seems to be associated with milder psoriasis 
forms, while the phenotypes with oligoamenorrhea with higher severity scores of 
disease [70].
For PCOS screening and diagnosis two of the following criteria are sufficient: 
oligo- or anovulation, biochemical or clinical hyperandrogenism, and polycystic 
ovaries on ultrasound examination [71].
4.10 Screening of metabolic syndrome
Genetic susceptibility, inflammatory pathways and common environmental fac-
tors (tobacco smoking, alcohol consumption, psychological stress and low physical 
activity) are responsible for the development of psoriasis and metabolic comorbidi-
ties. These disorders share similar pathophysiological phenomena: chronic inflam-
mation with high production of pro-inflammatory cytokines (especially TNF-alpha, 
IFN-gamma, IL-1, IL-2, IL-6, IL-8 and IL-17) that induces angiogenesis, adipogen-
esis, oxidative stress, insulin signaling, lipid metabolism and immune cell traffic 
[72, 73]. Metabolic aspects of chronic inflammation Th-1/Th-17 in psoriasis would 
have a role of predisposition and reciprocal aggravation on other conditions, such as 
obesity, diabetes and atherosclerosis [74].
Literature data prove in large observational studies the association of psoriasis to 
increased prevalence of metabolic syndrome, as well as its individual components: 
central obesity, atherogenic dyslipidemia, hypertension and insulin resistance [75, 76]. 
Severe psoriasis cases present higher chances for the development of metabolic syn-
drome, compared to mild forms of the disease [77].
Obesity or weight gain has been shown to be an independent risk factor 
for psoriasis. As obesity is also associated with reduced efficacy of psoriasis 
treatment, weight loss intervention programs should be included in psoriasis 
management.
Latest review on the topic emphasize the critical need for providers to screen 
psoriasis patients for cardio metabolic diseases, using the criteria abdominal 
circumference (>102 cm in males, >88 in females) plus two of the following: low 
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HDL-cholesterol (<40 mg/dL men, <50 mg/dL in women), hypertriglyceridemia 
(≥150 mg/dL), high blood pressure (≥130/85 mmHg) or high fasting glucose 
(≥110 mg/dL). The guidelines recommend annual measuring of waist circumfer-
ence, quarterly determination of fasting lipids and glucose, monthly measurement 
of weight, body mass index and blood pressure. Screening is useful in patients with 
risk factors: female gender, advancing age, illiteracy, unemployment, positive fam-
ily history, obesity and a sedentary lifestyle [78].
4.11 Screening for diabetes mellitus type 2
It is believed that fat cells in psoriasis patients secrete cytokines that raise insulin 
resistance in the liver and muscle, which initiates the destruction of the insulin-
producing beta cells in the pancreas [79].
Several observational studies have investigated the association between dia-
betes mellitus type 2 and psoriasis or psoriatic arthritis(PsA). The highest risk for 
diabetes mellitus type 2 was detected for patients suffering from PsA Literature 
data indicated a dose effect in the risk of suffering from type 2 diabetes mellitus, as 
patients having severe psoriasis had higher risk [80].
Screening of patients for diabetes mellitus type 2 is recommended annually in.
patients over 45 years or in patients younger than 45 years with major risk 
factors (positive family history, overweight, high blood pressure, etc.), and 
every 3 years for obese patients regardless of risk factors. Guidelines recommend 
a diagnostic of diabetes mellitus to be established with: single random plasma 
glucose level ≥ 200 mg/dL plus typical symptoms of hyperglycemia, while 
determinations should be repeated on the next day for the following situations: 
a fasting plasma glucose level ≥ 126 mg/dL; an A1C level of 6.5% or greater; a 
random plasma glucose level ≥ 200 mg/dL; a 75-g 2-hour oral glucose tolerance 
test with a plasma glucose level ≥ 200 mg/dL [81].
4.12 Screening for cardiovascular diseases
Psoriasis seems to be associated with cardiovascular and metabolic comorbidi-
ties, particularly in young patients and patients with more severe forms of the 
disease. Psoriasis patients have a twice as high risk to develop a cardiovascular 
disease, maybe due to the increased burden of subclinical atherosclerosis and 
vascular inflammation [76]. Psoriasis seems to be associated with atrial fibrillation 
and stroke, which may be aggravated in young patients. Studies noted significantly 
higher levels of serum lipids, including triglycerides and total cholesterol in psoria-
sis patients compared to healthy controls [82].
For screening of cardiovascular diseases (coronary artery disease being the 
most common heart disease) the completion of the Framingham 10 Year Risk of 
General Cardiovascular Disease Score and the dosing of the following parameters 
are necessary: LDL cholesterol and HDL cholesterol (every 4–6 years for normal 
risk patients), blood glucose level (start annual screening at 45 years old if normal 
weight or at 40 years old if obese) and amount of high-sensitivity C-reactive 
protein (used for those with intermediate risk, up to 20%, of having a heart attack 
within the next 10 years), blood pressure level determination (every 2 years if 
values are under 120/80 mmHg). Additional testing is required in the presence of 
risk factors (increased cholesterol, increased high blood pressure, diabetes, obesity, 
cigarette smoking, family history of premature disease in a first-degree relative) 
and it includes: electrocardiography (ECG), exercise cardiac stress test, echocar-
diography, coronary CR angiography, etc.
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4.13 Screening for nonalcoholic fatty liver disease
Observational studies suggest that patients with psoriasis are up to threefold.
more likely to have fatty liver disease over controls. An explanation could be the 
fact that proinflammatory adipokines or skin-derived cytokines may lead to insulin 
resistance and hepatic lipid accumulation [83].
Patients with nonalcoholic fatty liver disease and psoriasis have more severe skin 
disease and are at higher risk of severe liver fibrosis than patients without psoriasis.
The risk was significantly correlated with obesity, insulin resistance, and meta-
bolic syndrome and psoriatic arthritis [84].
As nonalcoholic fatty liver disease causes no symptoms in most cases, it is 
frequently diagnosed without this certain purpose. Liver screening includes liver 
enzyme and liver function tests, tests for chronic viral hepatitis (hepatitis A, hepati-
tis C and others), plain ultrasound showing steatosis. A liver biopsy is necessary 
in order to distinguishing NASH from other forms of liver disease. Non-invasive 
diagnostic tests are available: FibroTest for estimating liver fibrosis and SteatoTest 
for estimating steatosis [85].
4.14 Endocrine assessment in psoriasis
It is well known that the nervous system, the endocrine system and the skin 
have the same embryological origin, from the ectoderm [86]. Also, the function 
and the normal development of the skin are influenced by hormones, among them 
sex hormones, thyroid hormones or stress hormones [87]. Literature data present 
different endocrine conditions in association with psoriasis onset or exacerbation. 
Thus, a complete assessment of psoriatic patients should be performed, in order to 
identify concomitant disorders that can sustain or trigger psoriasis.
4.14.1 Estradiol
The involvement of sex hormones in psoriasis was taken into consideration 
due to the fact that the incidence of this chronic disease is higher in time periods 
characterized by hormonal imbalance, such as puberty, postpartum or menopause 
[88–90].
Thus, a significant correlation was found by Murase et al. between estradiol 
and psoriasis body surface area (BSA), with the improvement of the disease dur-
ing pregnancy [7]. Also, a cohort study, published in 2016, suggested a possible 
association between hormonal imbalance, induced by irregular menstrual cycles or 
surgical menopause, and psoriasis risk in women [91].
Testing the level of estradiol in male patients with psoriasis, Cemil et al. found 
an inverse correlation between the severity of the disease, evaluated by PASI score, 
and the level of hormones [92].
4.14.2 Prolactin (PRL)
This pituitary hormone involved in reproduction and lactation exerts immu-
nomodulatory effects also, being considered a member of type I cytokine family 
[93]. Several observations that sustain the role of PRL in psoriasis pathogenesis are 
linked, first, with the exacerbation of the disease due to prolactinoma development, 
secondly, with lesions remission in the context of bromcriptine administration, a 
dopaminergic inhibitor of PRL secretion [87].
The level of PRL in psoriasis patients was assessed in different studies and 
compared with controls. The correlation with PASI score was also evaluated, but 
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the results were contradictory, as it is shown in the first meta-analysis regarding 
this topic. However, the conclusions of this recent study sustain the significantly 
increased level of PRL in psoriasis patients compared to controls and the positive 
association with PASI [94].
4.14.3 Thyroid and thyroid hormones
The involvement of thyroid hormones in skin homeostasis is suggested by the 
variety of modifications associated with thyroid disorders, whether hyperthyroid-
ism or hypothyroidism. Moreover, literature data confirm the presence of thyroid 
hormones receptors in the skin and the stimulatory effect upon epidermal growth 
factor, with the consequent keratinocytes hyperproliferation [95].
Thus, in several studies, an evaluation of thyroid function was performed in 
patients with psoriatic disease. Among these studies some case reports suggest 
the benefits of antithyroid drugs (e.g. propylthiouracil) in psoriasis evolution, or 
resolution of the disease after thyroidectomy [87].
Recent data presented a higher incidence of new cases of thyroid disorders (small 
thyroid, positive antithyroidperoxidase antibody-AbTPO, hypothyroidism) in 
patients with psoriatic arthritis, particularly in women, compared to control group. 
The females at risk are those with a level of thyroid-stimulating hormone (TSH) at 
the superior limit of the normal range, positive AbTPO or a small volume of thyroid 
gland [96]. The association between autoimmune thyroid disease and the prevalence 
of psoriatic disease was also suggested as a conclusion in a meta-analysis from 2017, 
due to Th1 immune predominance and high circulating levels of CXCL10 [97].
4.14.4 Stress hormones
Stress is one of the major factors that may trigger/exacerbate psoriasis lesions. 
The mechanisms include the activation of hypothalamic–pituitary–adrenocortical 
(HPA) axis and the sympathoadrenomodulatory system (SAM), with the conse-
quent release of proinflammatory cytokines. Cortisol is an indicator of HPA activ-
ity. In patients with psoriasis the cortisol response to stress is lower than in controls 
[87]. Also, they present increased levels of epinephrine and adrenocorticotropic 
hormone, which seem to be involved in maintaining and exacerbation of psoriasis 
lesions [98]. Moreover, the cutaneous glucosteroidogenesis is also defective in 
patients with psoriasis, which favors the specific clinical aspect of the lesions [99].
5. Diseases severity evaluation using common scales
5.1 Dermatologic assessment of disease severity
For psoriasis severity assessment, more than 40 different tools have been used. 
Commonly used measures by the dermatologist include: the Psoriasis Area and 
Severity Index (PASI), body surface area (BSA), the Physician Global Assessment 
(IGA) or the simplified Lattice-System Physician’s Global Assessment (LS-PGA) 
and The Nail Psoriasis Severity Index (NAPSI) [100]. The patients can also assess 
the disease, using the Self-Administered PASI (SAPASI). Unfortunately, none of the 
currently published severity scores for psoriasis meets all the criteria required for an 
ideal score, and for a reliable assessment of psoriasis severity several independent 
evaluations are performed simultaneously [101].
Mild psoriasis is considered if it covers less than 3% of the body, moderate 
form, if 3–10% of the body has psoriasis lesions, and severe if psoriasis lesions are 
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present on more than 10% of the body. Disease severity cohorts were categorized 
based on PASI severity scores as follows: mild disease with PASI up to 5, moderate 
form with PASI score from 5 to 12, severe form between 12 and 20 PASI score, very 
severe over 20.
5.1.1 Psoriasis area and severity index (PASI) and BSA
PASI represents the most widely used tool for the measurement of the physi-
cal extent and severity of the disease (higher PASI scores indicate more severe 
psoriasis).PASI calculation consists of two major steps: calculating the BSA covered 
with lesions and the assessment of the lesions severity. The affected area and lesion 
characteristics generate a score from 0 to 72.
The amount of disease (BSA covered with lesions) is estimated by determin-
ing what percentage of the skin on a person’s body is affected, with the size of 
the palm of the hand equal to about 1 percent of the skin. The body of the patient 
is divided into four sections, each scored by itself: head (H) -representing 10% 
of the skin surface, arms (A) (20%), trunk (T) (30%), legs (L) (40%). For 
each section, a grade from 0 to 6 is attributed for the percent of skin involved: 
0—0% involvement, 2—less than 10%, 3—between 10 and 29% of involved area, 
4—between 30 and 49%, 5—between 50 and 69%, 6—between 70 and 89%, 7—
between 90 and 100%.
Within each area, the lesions severity is estimated by: erythema (redness), 
induration (thickness), desquamation (scaling), the severity of each parameter 
are noted on a scale from 0 (none) to 4 (maximum). The sum of all three severity 
parameters is then calculated for each section of skin, multiplied by the area score 
for that area, then multiplied by the weight of respective section (0.1 for head, 0.2 
for arms, 0.3 for body and 0.4 for legs) [101, 102].
PASI scores are used at baseline for entering a trial, and at follow-ups, to assess 
treatment efficacy and outcomes, usually expressed as a percentage response rate; 
for example, PASI 50, PASI 75, PASI 90, PASI 100. The PASI assessments were 
found to be non-reproducible and it was noticed that the physician’s estimations of 
the psoriatic lesion area tended to be overestimated.
The modified PASI which involves the computerized measurement of the 
area on the digital photograph is called Computer aided psoriasis continuous 
area and severity scores (cPcASI) and was successfully used in several clinical 
trials [103].
5.1.2 Physician global assessment (PGA)
Physician Global Assessment (PGA) is also called Investigator Global 
Assessment (IGA) and represents a 5 or 6-point ordinal rating scale, ranging from 
clear to severe psoriasis.
Score 0 means Cleared psoriasis, with no plaque elevation, erythema or scal-
ing, but hyperpigmentation may be present. Score 1 means Minimal psoriasis, 
with minimal plaque elevation (=0.25 mm), faint erythema, minimal scaling with 
occasional fine scale over <5% of lesion. Score 2 means Mild psoriasis with mild 
plaque elevation (−0.5 mm), light red coloration, fine scales predominates. Score 3 
means Moderate psoriasis with moderate plaque elevation (=0.75 mm), moderate 
red coloration, coarse scale predominates. Score 4 means Marked psoriasis, with 
moderate plaque elevation (=1 mm), bright red coloration, thick, nontenacious 
scales predominates. Score 5 means Severe psoriasis, with severe plaque elevation 
(>1.25 mm), dusky to deep red coloration, very thick and tenacious scale predomi-
nates [101, 102].
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5.1.3 Nail psoriasis severity index (NAPSI)
Nail Psoriasis Severity Index (NAPSI) represents a numeric, reproducible and 
objective tool used to evaluate the severity of nail bed psoriasis and nail matrix 
psoriasis by area of involvement in the nail unit., which is divided into quadrants 
by imaginary longitudinal and horizontal lines. The Nail plate is assessed for 
nail matrix psoriasis by the presence of: nail pitting, leukonychia, red spots in 
the lunula, and crumbling in each quadrant of the nail. The nail bed psoriasis is 
assessed by the presence of: onycholysis, oil drop (salmon patch) dyschromia, splin-
ter hemorrhages, and nail bed hyperkeratosis in each quadrant of the nail. Score 0 
means the findings are not present, Score 1 means they are present in one quadrant 
of the nail, Score 2 if present in two quadrants of a nail, 3 if present in three quad-
rants of a nail, and 4 if present in four quadrants of a nail. Each nail has a matrix 
score (0–4) and a nail bed score (0–4), and the total nail score is the sum of those 
two individual scores (0–8). The sum of the total score of all involved fingernails is 
the total NAPSI score of the psoriasis patient [104].
5.2 Assessment of psoriasis arthritis
Accurate and reliable methods are needed to measure disease activity, progres-
sion, and change with therapy in psoriatic arthritis (PsA). Some evaluation tools 
have been developed specifically for PsA, while others were borrowed and adapted 
from the fields of rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Key 
domains of interest for psoriasis arthritis assessment are joints, skin, enthesitis, 
dactylitis, spine, joint damage evaluated from the radiological, quality of life and 
functioning point of view. In 2007, the GRAPPA-OMERACT achieved consensus 
on 6 core domains that should be assessed in trials on subjects with PsA (peripheral 
joint activity, skin activity, pain, patient global assessment (PGA), physical function, 
and health-related quality of life) and other important but non mandatory domains 
(spinal disease, dactylitis, enthesitis, fatigue, nail disease, radiography, physician 
global assessment, and acute-phase reactants). Most of the clinical trials have used: 
the ACR scoring system, VAS scores of patient pain, patient global, physician global, 
the Health Assessment Questionnaire (HAQ ), and acute phase reactant, C-reactive 
protein (CRP) or erythrocyte sedimentation rate (ESR) [104, 105].
A PsA specific response index was developed and then improved and renamed 
as PsA specific response criteria PsARC. Two of the following were needed to 
achieve response in a psoriatic arthritis patient: a joint count and no worsening of 
any measure (tender or swollen joint count improvement of at least 30%, patient 
global improvement by one point on a five point Likert scale, or physician global 
improvement on the same scale).
Unlike the ACR criteria (only measuring change in disease activity), the DAS 
evaluation was useful in determining the current amount of disease activity. as well 
as the change of disease activity with therapy in RA. The original DAS used the 
Ritchie Articular Index (RAI), swollen joint count (SJC), ESR, and general health 
status (GH) (VAS) [106, 107].
5.3 Psychological assessment
Latest literature data report that psoriatic patients have a higher incidence of 
depression, anxiety, low self-esteem and social withdraw or isolation. Depression 
affects a high percentage of psoriasis patients and leads to chronic fatigue, loss of 
interest in life and everyday activities, appetite changes, sleep disturbances and 
negative coping mechanisms (use of alcohol and/or drugs, self-harm or other 
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high-risk behavior). Psoriasis patients may also face feelings of guilt, shame, 
embarrassment or helplessness and stress (which can trigger flares of psoriasis). 
Sexual dysfunction may occur due to self-consciousness or painful lesions, which 
can also interface with activities of daily living, including dressing, bathing and 
sleeping. Psoriasis determines a negative impact on the patient’s family function-
ing, including financial hardship and degeneration of patient–family relationships. 
It may also generate decreased vocational opportunities due to discrimination or 
perceived restrictions on career choices, which can lead to employment and eco-
nomic difficulties. According to a national survey performed in USA on patients 
with severe forms of psoriasis: 20% said that their psoriasis contributed towards the 
loss of a job or resignation; 25% believed that their psoriasis has caused an intimate 
relationship to end; 43% said psoriasis had prevented them from making new 
friends; 83% expressed dissatisfaction with their current treatment [108].
Even if the dermatological condition can improve under treatment, the emo-
tional problems may persist or aggravate in some patients. Suicidal ideation, 
occurred in up to 10% of psoriasis patients. A significant number of psoriasis 
patients reported a negative mental and physical impact that is similar to cancer, 
hypertension, heart disease, depression and diabetes.
The negative impact of psoriasis can be measured by using the following instru-
ments: Dermatological Quality of Life Index (DQLI), Psoriasis Disability Index 
(PDI), The Family Psoriasis Index (PFI-14) questionnaire, the Health-Related 
Quality of Life (HRQoL) or SkinDex 29 or 17 [108].
6. Other laboratory studies
Laboratory studies and findings for psoriasis patients may include the following:
test for rheumatoid factor (RF) (usually negative result), erythrocyte sedimen-
tation rate (usually normal, except in pustular and erythrodermic psoriasis), uric 
acid level (may be elevated especially in pustular psoriasis, causing confusion with 
gout in psoriatic arthritis). If fluid is collected from the pustules, the results will 
indicate a sterile fluid with neutrophil infiltrate. Fungal studies can be performed, 
especially important in cases of hand and foot psoriasis that seem to be worsening 
with the use of topical steroids.
If starting systemic therapies such as immunological inhibitors, consider obtain-
ing baseline laboratory studies in pretreatment and when indicated by medical his-
tory or physical examination findings (usually every 2–5 months): blood count (Hb, 
Htc, leucocytes, platelets, differential blood count), CRP, liver enzymes (ALT, AST, 
AP, γGT), serum creatinine/eGFR, urine status (including urine pregnancy test in 
females), as for hepatitis B, C, tuberculosis and HIV testing, they are optional only 
in some cases. Further specific testing may be required according to clinical signs, 
risk, and exposure.
7. Evaluation algorithm regarding treatment
There are three different algorithms regarding the evaluation of psoriasis 
patients related to treatment: pre-treatment, during-treatment and post-treatment.
Pre-treatment evaluation indications include: medical history (also checking 
for comedication) and physical examination with the objective assessment of the 
disease with specific scales (PASI/PGA, DLQI, etc.), performing laboratory controls 
(pregnancy test included), checking for skin cancer, evidence of active and chronic 
infection (exclusion of tuberculosis), checking for hypersensitivity, metabolic, 
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gastrointestinal and renal disorders, underweight or depression, check for contra-
ception and breastfeeding, need of vaccines.
During treatment evaluation indications include: medical history and physical 
examination (focusing on malignancies, infections, contraception, depression, 
anxiety) including the objective assessment of the disease with specific scales 
(PASI/PGA, DLQI, etc.), performing laboratory controls only when indicated on 
medical history or physical examination (tuberculosis testing included).
Post-treatment evaluation indications: discussing contraception (which can be 
pursued at least 20 weeks after discontinuation of biological treatment), continuing 
follow-up focusing on malignancies, infections, etc.
8. Conclusion
As a conclusion, care for psoriasis patients require more than the management of 
the skin lesions and of the joint involvement. The complexity of the disease requires 
a holistic approach of the patient, performed with utmost attention. Screening 
at regular intervals for associated diseases and prevention of comedication 
interactions, as well as recognition and avoidance of trigger factors, are essential. 
Psychosocial interventions, such as patient education and psychological treatment, 
may be needed in psoriasis management.
Author details
Meda Sandra Orasan1*, Iulia Ioana Roman2 and Andrei Coneac3
1 Department of Physiopathology, Iuliu Hatieganu University of Medicine and 
Pharmacy, Cluj-Napoca, Romania
2 Department of Physiology, Iuliu Hatieganu University of Medicine and Pharmacy, 
Cluj-Napoca, Romania
3 Department of Histology, Iuliu Hatieganu University of Medicine and Pharmacy, 
Cluj-Napoca, Romania
*Address all correspondence to: meda2002m@yahoo.com
20
Tailored Treatments in Psoriatic Patients
References
[1] Parisi R, Symmons DP, Griffiths CE, 
Ashcroft DM. Global epidemiology 
of psoriasis: A systematic review 
of incidence and prevalence. The 
Journal of Investigative Dermatology. 
2013;133:377-385. DOI: 10.1038/
jid.2012.339
[2] Ogdie A, Gelfand J. Clinical risk 
factors for the development of psoriatic 
arthritis among patients with psoriasis: 
A review of available evidence. Current 
Rheumatology Reports. 2015;17(10):64. 
DOI: 10.1007/s11926-015-0540-1 
Available from: https://www.news-
medical.net/health/Psoriasis-Prognosis.
aspx
[3] Alexis AF, Blackcloud P. Psoriasis 
in skin of color: Epidemiology, 
genetics, clinical presentation, 
and treatment nuances. Journal of 
Clinical and Aesthetic Dermatology. 
2014;7(11):16-24
[4] Rachakonda TD, Schupp CW, 
Armstrong AW. Psoriasis prevalence 
among adults in the United States. 
Journal of the American Academy of 
Dermatology. 2014;70:512-516. DOI: 
10.1016/j.jaad.2013.11.013
[5] Global Report on Psoriasis. 
World Health Organization. 
2016. Available from: http://
apps.who.int/iris/bitstream/
handle/10665/204417/9789241565189_
eng.pdf;jsessionid=2A1681E8074FCD
0FC3345206D8FAA76F?sequence=1
[6] Nevitt GJ, Hutchinson PE. Psoriasis 
in the community: Prevalence, 
severity and patients’ beliefs and 
attitudes towards the disease. The 
British Journal of Dermatology. 
1996;135(4):533-537
[7] Murase JE, Chan KK, Garite TJ, 
Cooper DM, Weinstein GD. Hormonal 
effect on psoriasis in pregnancy and 
post partum. Archives of dermatology. 
2005;141:601-606. DOI: 10.1001/ 
archderm.141.5.601 
[8] Henseler T, Christophers E. Psoriasis 
of early and late onset: Characterization 
of two types of psoriasis vulgaris. 
Journal of the American Academy of 
Dermatology. 1985;13(3):450-456. DOI: 
10.1016/j.jaad.2013.11.013
[9] Zhao YE, Hu L, Ma JX, Xiao SX, Zhao 
YL. Investigation of the association 
between psoriasis and human leucocyte 
antigens A by means of meta-analysis. 
Journal of the European Academy 
of Dermatology and Venereology. 
2014;28(3):355-369. DOI: 10.1111/ 
jdv.12256
[10] Dinulos JGH. Chapter 152—
Psoriasis in Comprehensive Pediatric 
Hospital Medicine. Masby; 2007. pp. 
967-970
[11] Farber EM, Van Scott EJ. Psoriasis. 
In: Fitzpatrick TB, Eisen AZ, Wolff 
K, Freedberg IM, Austin KF, editors. 
Dermatology in General Medicine. 
2nd ed. New York: McGraw-Hill; 1979. 
pp. 233-252
[12] AlShobaili HA, Shahzad M, 
Al-Marshood A, Khalil A, Settin A, 
Barrimah I. Genetic background of 
psoriasis. International Journal of 
Health Sciences. 2010;4(1):23-29
[13] Sathyanarayana Rao TS, Basavaraj 
KH, Das K. Psychosomatic paradigms 
in psoriasis: Psoriasis, stress and 
mental health. Indian Journal of 
Psychiatry. 2013;55(4):313-315. DOI: 
10.4103/0019-5545.120531
[14] Mallbris L, Larsson P, Bergqvist 
S, Vingård E, Granath F, Ståhle 
M. Psoriasis phenotype at disease onset: 
Clinical characterization of 400 adult 
cases. The Journal of Investigative 
Dermatology. 2005;124(3):499-504. 
DOI: 10.1111/j.0022-202X.2004.23611.x
21
Evaluation of Psoriasis Patients
DOI: http://dx.doi.org/10.5772/intechopen.79763
[15] Basavaraj KH, Navya MA, Rashmi 
R. Stress and quality of life in psoriasis: 
An update. International Journal of 
Dermatology. 2011;50:783-792. DOI: 
10.1111/j.1365-4632.2010.04844.x
[16] National Psoriasis Foundation. 
About Psoriasis. 1996-2018. Available 
from: https://www.psoriasis.org/
about-psoriasis/causes
[17] Kelly-Sell M, Gudjonsson 
JE. Overview of psoriasis. In: 
Wu JJ, Feldman SR, Lebwohl 
MG, editors. Therapy for Severe 
Psoriasis. Philadelphia: Elsevier; 
2016. pp. 1-15. DOI: org/10.1016/
B978-0-323-44797-3.00001-3
[18] Bröms G, Haerskjold A, Granath F, 
Kieler H, Pedersen L, Berglind IA. 
Effect of maternal psoriasis on 
pregnancy and birth outcomes: A 
population-based cohort study from 
Denmark and Sweden. Acta Dermato-
Venereologica. 2018 Mar 15. DOI: 
10.2340/00015555-2923. [Epub ahead of 
print]
[19] Psoriasis Clinical Presentation. 
2018. Available from: https://
emedicine.medscape.com/
article/1943419-clinical#b1
[20] Fletcher T. Psoriasis and psoriatic 
arthritis alliance (PAPAA). The 
Psychosocial Burden of Psoriasis. 
2013. Available from: www.papaa.org/
articles/psychosocial-burden-psoriasis 
[Accessed: Jan 31, 2017]
[21] Levenson J. Psychiatric issues 
in dermatology, part one: Atopic 
dermatitis and psoriasis. In: Primary 
Psychiatry. 2008. Available from: www.
primarypsychiatry.com/psychiatric-
issues-in-dermatology-part-1-atopic-
dermatitis-and-psoriasis [Accessed: Jan 
31, 2017]
[22] Ryan C, Korman NJ, Gelfand JM, 
Lim HW, Elmets CA, Feldman SR, 
Gottlieb AB, Koo JY, Lebwohl M, 
Leonardi CL, Van Voorhees AS, Bhushan 
R, Menter A. Research gaps in psoriasis: 
Opportunities for future studies. 
Journal of the American Academy of 
Dermatology. 2014;70:146-167.  
DOI: 10.1016/j.jaad.2013.08.042
[23] Gisondi P, Di Mercurio M, Idolazzi 
L, Girolomoni G. Concept of remission 
in chronic plaque psoriasis. The 
Journal of Rheumatology. Supplement. 
2015;93:57-60. DOI: 10.3899/
jrheum.150638
[24] Oliveira Mde F, Rocha Bde O, 
Duarte GV. Psoriasis: Classical 
and emerging co-morbidities. 
Anais Brasileiros de Dermatologia. 
2015;90:9-20. DOI: 10.1590/
abd1806-4841.20153038
[25] Dubertret L, Mrowietz U, Ranki 
A, van de Kerkhof PC, Chimenti S, 
Lotti T, Schäfer G. European patient 
perspectives on the impact of psoriasis: 
The EUROPSO patient membership 
survey. The British Journal of 
Dermatology;155(4):729-736. DOI: 
10.1111/j.1365-2133.2006.07405.x
[26] Pariser D, Schenkel B, Carter C, 
Farahi K, Brown TM, Ellis CN, Psoriasis 
Patient Interview Study Group. A 
multicenter, non-interventional 
study to evaluate patient-reported 
experiences of living with psoriasis. 
The Journal of Dermatological 
Treatment. 2016;27:19-26. DOI: 
10.3109/09546634.2015.1044492
[27] Schaefer I, Rustenbach S, 
Radtke M, Augustin J, Glaeske 
G, Augustin M. Epidemiologie 
der Psoriasis in Deutschland—
Auswertung von Sekundardaten einer 
gesetzlichen Krankenversicherung. 
Gesundheitswesen. 2011;73:308-313
[28] Kubota K, Kamijima Y, Sato T, 
Ooba N, Koide D, Iizuka H, Nakagawa 
H. Epidemiology of psoriasis and 
palmoplantarpustulosis: A nationwide 
study using the Japanese national claims 
Tailored Treatments in Psoriatic Patients
22
database. BMJ Open. 2015;5:e006450. 
DOI: 10.1136/bmjopen-2014-00 
6450
[29] Danielsen K, Olsen AO, Wilsgaard 
T, Furberg AS. Is the prevalence 
of psoriasis increasing? A 30-year 
follow-up ofa population-based cohort. 
The British Journal of Dermatology. 
2013;168:1303-1310. DOI: 10.1111/
bjd.12230
[30] Alshami MA. Clinical profile 
of psoriasis in Yemen, a 4-year 
retrospective study of 241 patients. 
Journal of the European Academy 
of Dermatology and Venereology. 
2010;24:14
[31] Moradi M, Rencz F, Brodszky V, 
Moradi A, Balogh O, Gulacsi L. Health 
status and quality of life in patients with 
psoriasis: An Iranian cross-sectional 
survey. Archives of Iranian Medicine. 
2015;18(3):153-159. DOI: 0151803/
AIM.004
[32] GoodHeart HP. Photoguide to 
common skin disorders. In: Diagnostic 
and Management. Philadelphia: 
Lippincott Williams & Wilkins; 2009. 
p. 756
[33] Falodun OA. Characteristics of 
patients with psoriasis seen at the 
dermatology clinic of a tertiary hospital 
in Nigeria: A 4-year review 2008-2012. 
Journal of the European Academy 
of Dermatology and Venereology. 
2013;27:43
[34] Natarajan V, Nath AK, Thappa 
DM, Singh R, Verma SK. Coexistence 
of onychomycosis in psoriatic nails: 
A descriptive study. Indian Journal 
of Dermatology, Venereology 
and Leprology. 2010;76:723. DOI: 
10.4103/0378-6323.72468
[35] Augustin M, Reich K, Blome C, 
Schafer I, Laass A, Radtke MA. Nail 
psoriasis in Germany: Epidemiology and 
burden of disease. The British Journal 
of Dermatology. 2010;163(3):580-585. 
DOI: 10.1111/j.1365-2133.2010.0 
9831.x
[36] Fatahzadeh M, Schwartz RA. Oral 
psoriasis: An overlooked enigma. 
Dermatology. 2016;232:319-325. DOI: 
10.1159/000444850
[37] Why Is A Biopsy Needed? 2016. 
Available from: https:// plaquepsoriasis.
com/ diagnosis-confirm-test-biopsy- 
rule-out/
[38] Psoriasis Workup. 2018. Available 
from: https://emedicine.medscape.com/
article/1943419-workup#c2
[39] Elston DM, Ferringer T, Ko C, 
Peckham S, High W, DiCaudo D. 
Dermatopathology. 2nd ed. 
Philadelphia, PA: Elsevier Saunders; 
2013
[40] Peter CM van der Kerkof. Psoriasis. 
In: Jean L. De Bolognia, Joseph L. 
Jorizzo, Ronald P, editors. Dermatology. 
Philadelphia: Mosby Elsevier; 2003. pp. 
125-151
[41] Maitray A, Bhandary AS, Shetty 
SB, Kundu G. Ocular manifestations 
in psoriasis. International Journal of 
Ocular Oncology and Oculoplasty. 
2016;2:123-131
[42] Kilic B, Dogan U, Parlak AH, 
Goksugur N, Polat M, Serin D, Ozmen 
S. Ocular findings in patients with 
psoriasis. International Journal of 
Dermatology. 2013;52:554-559. DOI: 
10.1111/j.1365-4632.2011.05424.x
[43] Rosenbaum JT, Lin P, Asquith 
M. Does the microbiome cause 
B27-related acute anterior 
uveitis? Ocular Immunology and 
Inflammation. 2016;22:1-5. DOI: 
10.3109/09273948.2016.1142574
[44] Wilson F, Icen M, Crowson 
C, McEvoy M, Gabriel S, Kremers 
H. Incidence and clinical predictors 
23
Evaluation of Psoriasis Patients
DOI: http://dx.doi.org/10.5772/intechopen.79763
of psoriatic arthritis in patients 
with psoriasis: A population-based 
study. Arthritis and Rheumatism. 
2009;61(2):233-239. DOI: 10.1002/
art.24172
[45] Langenbruch A, Radtke MA, 
Krensel M, Jacobi A, Reich K, 
Augustin M. Nail involvement as a 
predictor of concomitant psoriatic 
arthritis in patients with psoriasis. 
The British Journal of Dermatology. 
2014;171:1123-1128. DOI: 10.1111/
bjd.13272
[46] Soltani-Arabshahi R, Wong B, 
Feng B, Goldgar D, Duffin K, Krueger 
G. Obesity in early adulthood as a risk 
factor for psoriatic arthritis. Archives of 
Dermatology. 2010;146:721-726. DOI: 
10.1001/archdermatol.2010.141
[47] Wolinsky C, Lebwohl M. Biologic 
therapy and the risk of malignancy 
in psoriasis. Psoriasis Forum. 
2011;17:238-253
[48] Margolis D, Bilker W, Hennessy S, 
Vittorio C, Santanna J, Strom BL. The 
risk of malignancy associated with 
psoriasis. Archives of Dermatology. 
2001;137:778-783
[49] Gelfand JM, Shin DB, Neimann AL, 
Wang X, Margolis DJ, Troxel AB. The 
risk of lymphoma in patients with 
psoriasis. The Journal of Investigative 
Dermatology. 2006;126:2194-2201. DOI: 
10.1038/sj.jid.5700410
[50] Chiesa Fuxench ZC, Shin DB, 
Beatty AO, Gelfand JM. The risk of 
cancer in patients with psoriasis: 
A population-based cohort 
study in the health improvement 
network. JAMA Dermatology. 
2016;152:282-290. DOI: 10.1001/
jamadermatol.2015.4847
[51] Osmancevic A, Gillstedt M, 
Wennberg AM, Larko O. The risk 
of skin cancer in psoriasis patients 
treated with UVB therapy. Acta 
Dermato-Venereologica. 2014;94:425-
430. DOI: 10.2340/00015555-1753
[52] Wolfe F, Michaud K. Biologic 
treatment of rheumatoid arthritis and 
the risk of malignancy: Analyses from a 
large US observational study. Arthritis 
and Rheumatism. 2007;56:2886-2895. 
DOI: 10.1002/art.22864
[53] Lima XT, Seidler EM, Lima HC, 
Kimball AB. Long-term safety of 
biologics in dermatology. Dermatologic 
Therapy. 2009;22:2-21. DOI: 
10.1111/j.1529-8019.2008.01213.x
[54] Morar N, Willis-Owen SA, Maurer 
T, Bunker CB. HIV-associated psoriasis: 
Pathogenesis, clinical features, and 
management. The Lancet Infectious 
Diseases. 2010;10:470-478
[55] Ahn C, Dothard E, Garner M, 
Feldman S, Huang W. Screening 
and monitoring tests during the 
use of biologic agents to treat 
psoriasis and psoriatic arthritis: An 
evidence-based assessment of current 
recommendations. Journal of the 
American Academy of Dermatology. 
2015;72(5):AB248 Available from: 
https://www.jaad.org/article/
S0190-9622(15)01109-3/fulltext
[56] Cheng HS, Rademaker 
M. Monitoring methotrexate-induced 
liver fibrosis in patients with psoriasis: 
Utility of transient elastography. 
Psoriasis (Auckl). 2018;8:21-29. DOI: 
10.2147/PTT.S141629
[57] Khan A, Haider I, Ayub M, 
Humayun M. Psoriatic arthritis is 
an indicator of significant renal 
damage in patients with psoriasis: An 
observational and epidemiological 
study. International Journal of 
Inflammation. 2017;2017:5217687. DOI: 
10.1155/2017/5217687
[58] González-Parra E, Daudén E, 
Carrascosa JM, Olveira A, Botella R, 
Bonanad C, Rivera R. Kidney disease 
Tailored Treatments in Psoriatic Patients
24
and psoriasis. A new comorbidity? Actas 
Dermo-Sifiliográficas. 2016;107:823-
829. DOI: 10.1016/j.ad.2016.05.009
[59] Dervisoglu E, Akturk AS, Yildiz 
K, Kiran R, Yilmaz A. The spectrum 
of renal abnormalities in patients with 
psoriasis. International Urology and 
Nephrology. 2012;44:509-514. DOI: 
10.1007/s11255-011-9966-1
[60] Lewis NR, Scott BB. Systematic 
review: The use of serology to 
exclude or diagnose coeliac disease 
(a comparison of the endomysial and 
tissue transglutaminase antibody 
tests). Alimentary Pharmacology & 
Therapeutics. 2006;24(1):47-54. DOI: 
10.1111/j.1365-2036.2006.02967.x
[61] Rostom A, Murray JA, Kagnoff 
MF. American Gastroenterological 
Association (AGA) Institute technical 
review on the diagnosis and management 
of celiac disease. Gastroenterology. 
2006;131:1981-2002. DOI: 10.1053/j.
gastro.2006.10.004. PMID 17087937
[62] Mackalski BA, Bernstein CN. 
New diagnostic imaging tools for 
inflammatory bowel disease. Gut. 
2005;55:733-741. DOI: 10.1136/ 
gut.2005.076612
[63] Israeli E1, Grotto I, Gilburd B, 
Balicer RD, Goldin E, Wiik A, Shoenfeld 
Y. Anti-saccharomyces cerevisiae and 
antineutrophil cytoplasmic antibodies 
as predictors of inflammatory bowel 
disease. Gut. 2005;54:1232-1236. DOI: 
10.1136/gut.2004.060228
[64] Kirby B1, Lyon CC, Griffiths CE, 
Chalmers RJ. The use of folic acid 
supplementation in psoriasis patients 
receiving methotrexate: A survey 
in the United Kingdom. Clinical 
and Experimental Dermatology. 
2000;25(4):265-268
[65] Fry L, Macdonald A, Almeyda 
J, Griffin CJ, Hoffbrand AV. The 
mechanism of folate deficiency in 
psoriasis. The British Journal of 
Dermatology. 1971;84:539-544
[66] Al-Dabagh A, Davis SA, Kinney 
MA, Huang K, Feldman SR. The 
effect of folate supplementation on 
methotrexate efficacy and toxicity in 
psoriasis patients and folic acid use by 
dermatologists in the USA. American 
Journal of Clinical Dermatology. 
2013;14:155-161. DOI: 10.1007/
s40257-013-0017-9
[67] Ungprasert P, Srivali N, 
Kittanamongkolchai W. Risk of 
Parkinson’s disease among patients 
with psoriasis: A systematic review 
and meta-analysis. Indian Journal of 
Dermatology. 2016;61:152-156. DOI: 
10.4103/0019-5154.177771
[68] Watanabe H, Hara K, Ito M, 
Katsuno M, Sobue G. New diagnostic 
criteria for Parkinson's disease: MDS-PD 
criteria. Brain and Nerve. 2018;70:139-
146. DOI: 10.11477/mf.1416200966
[69] Moro F, Tropea A, Scarinci E, 
Federico A, De Simone C, Caldarola 
G, Leoncini E, Boccia S, Lanzone A, 
Apa R. Psoriasis and polycystic ovary 
syndrome: A new link in different 
phenotypes. European Journal 
of Obstetrics, Gynecology, and 
Reproductive Biology. 2015;191:101-105. 
DOI: 10.1016/j.ejogrb.2015.06.002
[70] Isik S, Hiz MM, Kilic S, Cakir 
Gungor AN. A review on the 
link between psoriasis vulgaris 
and polycystic ovary syndrome. 
International Journal of Gynecology, 
Obstetrics and Neonatal Care. 
2016;3:9-14
[71] Gisondi P, Tessari G, Conti A, 
Piaserico S, Schianchi S, Peserico A, 
Giannetti A, Girolomoni G. Prevalence 
of metabolic syndrome in patients 
with psoriasis a hospital-based case-
control study. The British Journal of 
Dermatology. 2007;157:68-73. DOI: 
10.1111/j.1365-2133.2007.07986.x
25
Evaluation of Psoriasis Patients
DOI: http://dx.doi.org/10.5772/intechopen.79763
[72] Davidovici BB, Sattar N, Prinz 
J, Puig L, Emery P, Barker JN, van 
de Kerkhof P, Ståhle M, Nestle FO, 
Girolomoni G, Krueger JG. Psoriasis 
and systemic inflammatory diseases 
potential mechanistic links between 
skin disease and co-morbid conditions. 
The Journal of Investigative 
Dermatology. 2010;130:1785-1796. DOI: 
10.1038/jid.2010.103
[73] Carvalho AV, Romiti R, Souza CD, 
Paschoal RS, Milman LM, Meneghello LP. 
Psoriasis comorbidities: Complications 
and benefits of immunobiological 
treatment. Anais Brasileiros de 
Dermatologia. 2016;91:781-789. DOI: 
10.1590/abd1806-4841.20165080
[74] Gelfand JM, Yeung H. Metabolic 
syndrome in patients with psoriatic 
disease. The Journal of Rheumatology 
Supplement. 2012;89:24-28. DOI: 
10.3899/jrheum.120237
[75] Ryan C, Kirby B. Psoriasis is 
a systemic disease with multiple 
cardiovascular and metabolic 
comorbidities. Dermatologic Clinics. 
2015;33:41-55
[76] Armstrong AW, Harskamp CT, 
Armstrong EJ. Psoriasis and the risk of 
diabetes mellitus a systematic review 
and meta-analysis. JAMA Dermatology. 
2013;149:84-91
[77] Kaur J. Assessment and screening of 
the risk factors in metabolic syndrome. 
Medical Science. 2014;2:140-152. DOI: 
10.3390/medsci2030140
[78] Why stress happens and how 
to manage it. 2017. Available from: 
https://www.medicalnewstoday.com/
articles/145855.php
[79] Coto-Segura P1, Eiris-Salvado 
N, González-Lara L, Queiro-Silva R, 
Martinez-Camblor P, Maldonado-Seral 
C. Psoriasis, psoriatic arthritis and type 
2 diabetes mellitus: A systematic  
review and meta-analysis. The 
British Journal of Dermatology. 
2013;169(4):783-793. DOI: 10.1111/
bjd.12473
[80] Karly Pippitt MD, MD MLI, Gurgle 
HE. Diabetes mellitus: Screening and 
diagnosis. American Family Physician. 
2016;93(2):103-109
[81] Neimann AL, Shin DB, Wang 
X, Margolis DJ, Troxel AB, Gelfand 
JM. Prevalence of cardiovascular risk 
factors in patients with psoriasis. 
Journal of the American Academy of 
Dermatology. 2006;55:829-835
[82] Rinella ME. Nonalcoholic fatty 
liver disease: A systematic review. 
Journal of the American Medical 
Association (Systematic Review). 
2015;313(22):2263-2273
[83] Van der Voort EAM, Koehler EM, 
Dowlatshahi EA, et al. Psoriasis 
is independently associated with 
nonalcoholic fatty liver disease 
in patients 55 years old or older: 
Results from a population based 
study. Journal of the American Academy  
of Dermatology. 2014;70:517-524
[84] Sowa JP, Heider D, Bechmann 
LP, Gerken G, Hoffmann D, Canbay 
A. Novel algorithm for non-invasive 
assessment of fibrosis in NAFLD. PLoS 
One. 2013;8:624-639. DOI: 10.1371/
journal.pone.0062439
[85] Slominski AT, Zmijewski MA, 
Skobowiat C, Zbytek B, Slominski 
RM, Steketee JD. Sensing the 
environment: Regulation of local 
and global homeostasis by the skin’s 
neuroendocrine system. Advances 
in Anatomy, Embryology, and Cell 
Biology. 2012;212:1-115
[86] Roman II, Constantin AM, Marina 
ME, Orasan RI. The role of hormones in 
the pathogenesis of psoriasis vulgaris. 
Clujul Medical. 2016;89(1):11-18. DOI: 
10.15386/cjmed-505
Tailored Treatments in Psoriatic Patients
26
[87] Ceovic R, Mance M, Bukvic 
Mokos Z, Svetec M, Kostovic K, 
StulhoferBuzina D. Psoriasis: Female 
skin changes in various hormonal stages 
throughout life—Puberty, pregnancy, 
and menopause. BioMed Research 
International, vol. 2013, Article ID 
571912, 6 pages, 2013. https://doi.
org/10.1155/2013/571912
[88] Murase JE, Chan KK, Garite TJ, 
Cooper DM, Weinstein GD. Hormonal 
effect on psoriasis in pregnancy  
and postpartum. Archives of 
Dermatology. 2005;141(5):601-606. 
DOI: 10.1001/archderm.141. 
5.601
[89] Boehncke S, Salgo R, 
Garbaraviciene J, Beschmann H, 
Ackermann H, Boehncke WH, 
Ochsendorf FR. Changes in the sex 
hormone profile of male patients 
with moderate-to-severe plaque-
type psoriasis under systemic 
therapy: Results of a prospective 
longitudinal pilot study. Archives 
of Dermatological Research. 
2011;303(6):417-424. DOI: 10.1007/
s00403-011-1157-5
[90] Wu S, Cho E, Li W, Grodstein F, 
Qureshi AA. Hormonal factors and 
risk of psoriasis in women: A cohort 
study. Acta Dermato-Venereologica. 
2016;96(7):927-931. DOI: 
10.2340/00015555-2312
[91] Cemil BC, Cengiz FP, Atas H, 
Ozturk G, Canpolat F. Sex hormones 
in male psoriasis patients and their 
correlation with the psoriasis area 
and severity index. The Journal of 
Dermatology. 2015;42(5):500-503. DOI: 
10.1111/1346-8138.12803
[92] Langan EA1, Foitzik-Lau K, Goffin 
V, Ramot Y, Paus R. Prolactin: An 
emerging force along the cutaneous-
endocrine axis. Trends in Endocrinology 
and Metabolism. 2010;21(9):569-577. 
DOI: 10.1016/j.tem.2010.06.001
[93] Lee YH, Song GG. Association 
between circulating prolactin levels and 
psoriasis and its correlation with disease 
severity: A meta-analysis. Clinical 
and Experimental Dermatology. 2018 
Jan;43(1):27-35. DOI: 10.1111/ced.13228
[94] Contreras-Jurado C, García-
Serrano L, Gómez-Ferrería M, Costa 
C, Paramio JM, Aranda A. The thyroid 
hormone receptors as modulators of 
skin proliferation and inflammation. 
The Journal of Biological Chemistry. 
2011;286(27):24079-24088. DOI: 
10.1074/jbc.M111.218487
[95] Fallahi P, Ferrari SM, Ruffilli I, 
Elia G, Miccoli M, Sedie AD, Riente 
L, Antonelli A. Increased incidence 
of autoimmune thyroid disorders 
in patients with psoriatic arthritis: 
A longitudinal follow-up study. 
Immunologic Research. 2017;65(3):681-
686. DOI: 10.1007/s12026-017-8900-8
[96] Khan SR, Bano A, Wakkee M, 
Korevaar TIM, Franco OH, Nijsten TEC, 
Peeters RP, Chaker L. The association 
of autoimmune thyroid disease (AITD) 
with psoriatic disease: A prospective 
cohort study, systematic review and 
meta-analysis. European Journal of 
Endocrinology. 2017;177(4):347-359. 
DOI: 10.1530/EJE-17-0397
[97] Evers AW, Verhoeven EW, 
Kraaimaat FW, de Jong EM, de 
Brouwer SJ, Schalkwijk J, et al. How 
stress gets under the skin: Cortisol 
and stress reactivity in psoriasis. 
The British Journal of Dermatology. 
2010;163(5):986-991. DOI: 
10.1111/j.1365-2133.2010.09984.x
[98] Hannen R, Udeh-Momoh C, 
Upton J, Wright M, Michael A, Gulati 
A, Rajpopat S, Clayton N, Halsall 
D, Burrin J, Flower R, Sevilla L, 
Latorre V, Frame J, Lightman S, Perez 
P, Philpott M. Dysfunctional skin-
derived glucocorticoid synthesis is a 
pathogenic mechanism of psoriasis. The 
27
Evaluation of Psoriasis Patients
DOI: http://dx.doi.org/10.5772/intechopen.79763
Journal of Investigative Dermatology. 
2017;137(8):1630-1637. DOI: 10.1016/j.
jid.2017.02.984
[99] Carvalho AVE d, Romiti R, Silva 
Souza C d, Paschoal RS, Milman L d 
M, Meneghello LP. Global assessment 
of psoriasis severity and change from 
photographs: A valid and consistent 
method. The Journal of Investigative 
Dermatology. 2008;128(9): 
2198-2203
[100] Bożek A, Reich A. The reliability 
of three psoriasis assessment tools: 
Psoriasis area and severity index, 
body surface area and physician global 
assessment. Advances in Clinical and 
Experimental Medicine. 2017;26(5):851-
856. DOI: 10.17219/acem/69804
[101] Chow C, Simpson MJ, Luger TA, 
Chubb H, Ellis CN. Comparison of 
three methods for measuring psoriasis 
severity in clinical studies (part 1 of 2): 
Change during therapy in psoriasis area 
and severity index, static physician’s 
global assessment and lattice system 
physician’s global assessment. Journal of 
the European Academy of Dermatology 
and Venereology. 2015;29:1406-1414. 
DOI: 10.1111/jdv.13132
[102] Kreft S, Kreft M, Resman A, 
Marko P, Kreft KZ. Computer-aided 
measurement of psoriatic lesion area in 
a multicenter clinical trial—Comparison 
to physician's estimations. Journal of 
Dermatological Science. 2006;44(1):21-
27. [Epub Jul 5, 2006]. DOI: 10.1016/j.
jdermsci.2006.05.006
[103] Rich P, Scher RK. Nail psoriasis 
severity index: A useful tool for 
evaluation of nail psoriasis. Journal of 
the American Academy of Dermatology. 
2003;49(2):206-212
[104] van der Heijde DM, van’t Hof MA, 
van Riel PL, Theunisse LA, Lubberts 
EW, van Leeuwen MA, et al. Judging 
disease activity in clinical practice in 
rheumatoid arthritis: First step in the 
development of a disease activity score. 
Annals of the Rheumatic Diseases. 
1990;49:916-920
[105] Wong PCH, Leung Y-Y, Li EK, 
Tam L-S. Measuring disease activity in 
psoriatic arthritis. International Journal 
of Rheumatology. 2012;2012:839425. 
DOI: 10.1155/2012/839425
[106] Gladman DD, Cook RJ, Schentag C, 
et al. The clinical assessment of patients 
with psoriatic arthritis: Results of a 
reliability study of the spondyloarthritis 
research consortium of Canada. 
The Journal of Rheumatology. 
2004;31(6):1126-1131
[107] Bhosle MJ, Kulkarni A, Feldman 
SR, Balkrishnan R. Quality of life in 
patients with psoriasis. Health and 
Quality of Life Outcomes. 2006;4:35. 
DOI: 10.1186/1477-7525-4-35
[108] Gupta AK. Psychocutaneous 
disorders. In: Saddock B, Saddock V, 
Ruiz P, editors. Kaplan and Saddock's 
Comprehensive Textbook of Psychiatry. 
9th ed. Philadelphia, USA: Lippincotts; 
2009. pp. 2432-2433
